Rate of clinical progression in Parkinson's disease. A prospective study

被引:129
作者
Schrag, Anette [1 ]
Dodel, Richard
Spottke, Annika
Bornschein, Bernhard
Siebert, Uwe
Quinn, Niall P.
机构
[1] UCL, Dept Clin Neurosci, Royal Free Hosp, London NW3 2PF, England
[2] UCL, Dept Motor Neurosci & Movement Disorders, Inst Neurol, London, England
[3] Univ Marburg, Dept Neurol, Marburg, Germany
[4] UMIT Univ Hlth Sci Med Informat & Technol, Hall, Germany
[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA
关键词
Parkinson's disease; progression; UPDRS; scales;
D O I
10.1002/mds.21429
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate of clinical progression of PD in a clinic-based sample of 145 patients over 1 year and in a community-based sample of 124 patients over 4 years. Depending on the sample and clinical scale used, mean deterioration of motor and disability scores ranged from 2.4 to 7.4% of the maximum possible score per year, and standard deviations indicated that there was considerable variability of progression rates between individuals. The progression of motor scores decreased with follow-up over 4 years and significantly decreased in more advanced disease stages. Deterioration of disability scores did not differ between disease stages; this may reflect the increasing rate of disease complications, which contribute to increasing disability in addition to motor impairment alone, in more advanced disease. Thus, motor fluctuations, hallucinations, depression, memory problems, and bladder symptoms were all reported more often at follow-up in the community-based sample (all P < 0.01), and dyskinesias, motor fluctuations, falls, and hallucinations were more common and cognitive and depression scores worse in higher disease stages in the clinic-based sample (all P < 0.001). We conclude that progression of motor scores in PD decreases with advancing disease in PD. However, disability continues to deteriorate with advancing disease and with the development of disease complications that are likely to be related to additional extrastriatal pathology. (C) 2007 Movement Disorder Society.
引用
收藏
页码:938 / 945
页数:8
相关论文
共 50 条
  • [1] An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson's disease
    Morrish, PK
    Sawle, GV
    Brooks, DJ
    BRAIN, 1996, 119 : 585 - 591
  • [2] Clinical Measures of Progression in Parkinson's Disease
    Poewe, Werner
    MOVEMENT DISORDERS, 2009, 24 (14) : S671 - S676
  • [3] The clinical progression of Parkinson's disease
    Poewe, Werner
    Mahlknecht, Philipp
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S28 - S32
  • [4] Rate of cognitive decline in premotor Parkinson's disease: A prospective study (NEDICES)
    Sanchez-Ferro, Alvaro
    Benito-Leon, Julian
    Louis, Elan D.
    Mitchell, Alex J.
    Antonio Molina-Arjona, Jose
    Trincado, Rocio
    Villarejo, Alberto
    Bermejo-Pareja, Felix
    MOVEMENT DISORDERS, 2013, 28 (02) : 161 - 168
  • [5] Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation
    Chan, Phylinda L. S.
    Nutt, John G.
    Holford, Nicholas H. G.
    PHARMACEUTICAL RESEARCH, 2007, 24 (04) : 791 - 802
  • [6] Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation
    Phylinda L. S. Chan
    John G. Nutt
    Nicholas H. G. Holford
    Pharmaceutical Research, 2007, 24 : 791 - 802
  • [7] Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study
    Marques, Ana
    Macias, Elise
    Pereira, Bruno
    Durand, Elodie
    Chassain, Carine
    Vidal, Tiphaine
    Defebvre, Luc
    Carriere, Nicolas
    Fraix, Valerie
    Moro, Elena
    Thobois, Stephane
    Metereau, Elise
    Mangone, Graziella
    Vidailhet, Marie
    Corvol, Jean-Christophe
    Lehericy, Stephane
    de Champfleur, Nicolas Menjot
    Geny, Christian
    Spampinato, Umberto
    Meissner, Wassilios G.
    Frismand, Solene
    Schmitt, Emmanuelle
    de Maindreville, Anne Doe
    Portefaix, Christophe
    Remy, Philippe
    Fenelon, Gilles
    Houeto, Jean Luc
    Colin, Olivier
    Rascol, Olivier
    Peran, Patrice
    Bonny, Jean-Marie
    Fantini, Maria Livia
    Durif, Franck
    JOURNAL OF NEUROLOGY, 2023, 270 (12) : 6033 - 6043
  • [8] Effect of diabetes control status on the progression of Parkinson's disease: A prospective study
    Ou, Ruwei
    Wei, Qianqian
    Hou, Yanbing
    Zhang, Lingyu
    Liu, Kuncheng
    Lin, Junyu
    Jiang, Zheng
    Song, Wei
    Cao, Bei
    Shang, Huifang
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2021, 8 (04): : 887 - 897
  • [9] Predictors associated with the rate of progression of nigrostriatal degeneration in Parkinson's disease
    Yoo, Han Soo
    Kim, Han-Kyeol
    Lee, Hye Sun
    Yoon, So Hoon
    Na, Han Kyu
    Kang, Sung Woo
    Lee, Jae-Hoon
    Ryu, Young Hoon
    Lyoo, Chul Hyoung
    JOURNAL OF NEUROLOGY, 2024, 271 (08) : 5213 - 5222
  • [10] Exploring determinants of progression in Parkinson's disease. Is there a difference among Jewish ethnic groups?
    Orlev, Y.
    Yahalom, G.
    Cohen, O. S.
    Elincx-Benizri, S.
    Kozlova, E.
    Inzelberg, R.
    Goldbourt, U.
    Hassin-Baer, S.
    PARKINSONISM & RELATED DISORDERS, 2015, 21 (03) : 184 - 188